Piper Jaffray analyst Christopher Raymond is “incrementally positive” on BioMarin shares after the company disclosed at a conference today that it plans to file for accelerated approval of Valrox, the company’s hemophilia gene therapy, in the second half of 2019. The analyst notes this is a full year earlier than he currently models. Pulling Valrox forward by one year adds approximately $10 per share to the stock, Raymond tells investors in a research note. He keeps an Overweight rating on BioMarin with a $120 price target. The stock in early trading is up 2c to $96.62.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.